April 15 (Reuters) - U.S.-based hedge fund Shah Capital wrote to the Novavax board on Monday to push for the instalment of two new independent board directors, the Financial Times reported on Monday.
Shah Capital also wants a pivot in the biotech company's sales strategy for its Covid-19 shot, which is based on traditional vaccine technology, to target older people unnerved by rare side effects associated with mRNA jabs from Pfizer and Moderna, FT reported citing a letter.
(Reporting by Disha Mishra in Bengaluru; Editing by Mrigank Dhaniwala)
((Disha.Mishra@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments